Basic Information

Faculty

• 医学部

Professional Memberships

• To Present

  The Molecular Biology Society of Japan
• To Present

  American Society of Clinical Oncology (ASCO)
• To Present

  American Association for Cancer Research (AACR)
• To Present

  日本胃癌学会
• To Present

  日本癌治療学会
• To Present

  日本癌学会
• To Present

  日本臨床腫瘍学会
• To Present

  日本消化器病学会
• To Present

  日本内科学会

Academic Degree

• 博士（医学）(京都大学)

Research History

• From Jan. 2024, To Present

  Kyoto University Graduate School of Medicine, Department of Medical Oncology, Associate Professor
• From 2020, To Jan. 2024

  Kyoto University Graduate School of Medicine, Department of Therapeutic Oncology, Senior Lecturer
• From 2016, To 2019

  Kyoto University Graduate School of Medicine, Department of Therapeutic Oncology, Program Specific Assistant Professor
• From Sep. 2011, To Mar. 2016

  Stanford University, Institute for Stem Cell Biology & Regenerative Medicine, Postdoctoral Researcher
• From Apr. 2011, To Mar. 2013

  Japan Society for the Promotion of Science, Postdoctoral Researcher
• From Apr. 2007, To Mar. 2010

  National Cancer Center Research Institute, Chemotherapy Division, Research Resident
• From Apr. 2005, To Mar. 2007

  National Cancer Center Hospital, 消化管内科, がん専門修練医
• From Apr. 2004, To Mar. 2005

  National Cancer Center Hospital, 肝胆膵内科, 研修医
• From Apr. 2002, To Mar. 2004

  聖路加国際病院, 消化器内科
• From May 2000, To Mar. 2002

  神戸市立医療センター中央市民病院, 内科研修医

Language of Instruction

• English
• Japanese

ID,URL

• J-Global ID

  201601011253219730

researchmap URL

• https://researchmap.jp/junichimatsubara

Research

Research Topics, Overview of the research

• Research Topics

  Biomarker study to enhance the personalized cancer chemotherapy.
  Functional analysis of the molecules involved in the DNA-damaging response and cell-cycle arrest.

• Overview of the research

  消化器がん化学療法における治療個別化マーカーの開発を目指し、ヒト検体を用いた様々な研究を行っている。
  細胞周期停止応答とDNA損傷修復機構に関わる分子の中で、細胞周期停止応答を担う分子を阻害して抗がん剤による殺細胞効果を高める臨床データが最近報告されている。われわれは、これまで阻害剤が開発されていないある細胞周期停止応答タンパクに着目し、in silico解析による新しい化合物のスクリーニング、およびその化合物と抗がん剤の併用相乗効果のin vitro / in vivo validationを行い、新しい抗がん治療戦略の確立を目指して研究を行っている。

Research Interests

• Clinical Oncology
• Cancer Genome Profiling
• Cancer Stem Cell
• Cancer Chemotherapy

Research Areas

• Life sciences, Tumor diagnostics and therapeutics
• Life sciences, Gastroenterology
• Life sciences, Tumor biology

Papers

• The nationwide survey of Japanese public opinion about off-label use of anticancer drugs recommended by comprehensive genomic profiling.

  Junichi Matsubara; Kumi Mukai; Manabu Muto

  International journal of clinical oncology, 18 Jul. 2025, Peer-reviewed, Lead author

  
• An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.

  Shigenori Kadowaki; Tomoyuki Otsuka; Keiko Minashi; Shinichi Nishina; Hiroshi Yabusaki; Chiaki Inagaki; Tomohiro Nishina; Hisateru Yasui; Hiroshi Matsuoka; Nozomu Machida; Masahiro Tsuda; Fumio Nagashima; Hisashi Hosaka; Junichi Matsubara; Hiroyuki Arai; Satoshi Ida; Yuya Kimijima; Yuko Matsuda; Manabu Muto; Kei Muro

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 09 Jul. 2025, Peer-reviewed

  
• First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors: 1-Year Follow-Up of the FIRST-Dx Study

  Junichi Matsubara; Kumi Mukai; Tomohiro Kondo; Masahiro Yoshioka; Hidenori Kage; Katsutoshi Oda; Sadakatsu Ikeda; Hiromichi Ebi; Kei Muro; Shinya Kajiura; Ryuji Hayashi; Reiko Ashida; Masayuki Kitano; Manabu Muto

  Cancer Science, 11 Apr. 2025, Peer-reviewed, Lead author

  
• Proposing Oligo-Recurrence Criteria in Pancreatic Ductal Adenocarcinoma: A Stratified Analysis of Locoregional Treatment Benefits

  Kei Yamane; Koshiro Morino; Takayuki Anazawa; Kazuyuki Nagai; Asahi Sato; Michio Yoshimura; Takahiro Iwai; Junichi Matsubara; Akihisa Fukuda; Hiroyoshi Isoda; Satoshi Ogiso; Yoichiro Uchida; Takashi Ito; Takamichi Ishii; Yu Hidaka; Yumiko Ibi; Etsuro Hatano

  Pancreatology, Apr. 2025

  
• Aldh2 and the tumor suppressor Trp53 play important roles in alcohol-induced squamous field cancerization

  Yuki Kondo; Shinya Ohashi; Chikatoshi Katada; Yukie Nakai; Yoshihiro Yamamoto; Masashi Tamaoki; Osamu Kikuchi; Atsushi Yamada; Kenshiro Hirohashi; Yosuke Mitani; Shigeki Kataoka; Tomoki Saito; Trang H. Nguyen Vu; Tomohiro Kondo; Yu Uneno; Tomohiko Sunami; Akira Yokoyama; Junichi Matsubara; Tomonari Matsuda; Seiji Naganuma; Kohei Oryu; Samuel Flashner; Masataka Shimonosono; Hiroshi Nakagawa; Manabu Muto

  Journal of Gastroenterology, 06 Feb. 2025

  Access this paper :

  
• Neoadjuvant Chemoradiotherapy Using Moderately Hypofractionated Intensity-Modulated Radiotherapy Versus Upfront Surgery for Resectable Pancreatic Cancer: A Retrospective Cohort Study

  Kei Yamane; Takayuki Anazawa; Kazuyuki Nagai; Yosuke Kasai; Toshihiko Masui; Aya Izuwa; Koki Kurahashi; Satoshi Ishida; Satoshi Ogiso; Michio Yoshimura; Takahiro Iwai; Junichi Matsubara; Akihisa Fukuda; Hiroyoshi Isoda; Yu Hidaka; Yumiko Ibi; Etsuro Hatano

  Annals of Surgical Oncology, 01 Feb. 2025

  Access this paper :

  
• The E2F4 transcriptional repressor is a key mechanistic regulator of colon cancer resistance toirinotecan(CPT-11)

  Junichi Matsubara; Yong Fuga Li; Sanjay Koul; Junko Mukohyama; Luis E. Valencia Salazar; Taichi Isobe; Dalong Qian; Michael F. Clarke; Debashis Sahoo; Russ B. Altman; Piero Dalerba

  bioRxiv, 24 Jan. 2025, Lead author

  
• 腫瘍組織のみを用いたがんゲノムプロファイリングにおける二次的所見疑いの確認検査

  近藤 知大; 山本 佳宏; 福山 啓太; 金井 雅史; 山田 敦; 松原 淳一; Pham Nguyen Quy; 吉岡 正博; 山田 崇弘; 南口 早智子; 松本 繁巳; 小杉 眞司; 武藤 学

  日本癌治療学会学術集会抄録集, Oct. 2023

  
• がんゲノム医療の現状と未来～多遺伝子パネル検査の臨床導入のインパクト～ 初回治療前の包括的ゲノム解析による個別化治療 FIRST-Dx試験の1年間の追跡データ

  蘆田 玲子; 松原 淳一; 向井 久美; 吉岡 正博; 鹿毛 秀宣; 織田 克利; 池田 貞勝; 衣斐 寛倫; 室 圭; 梶浦 新也; 林 龍二; 北野 雅之; 武藤 学

  日本癌治療学会学術集会抄録集, Oct. 2024

  
• SMARCA4-Deficient Poorly Differentiated Adenocarcinoma of the Gallbladder.

  Sho Koyasu; Akihiko Sugimoto; Junichi Matsubara; Manabu Muto; Yuji Nakamoto

  Clinical nuclear medicine, 01 Jul. 2024

  
• Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study.

  Mari Yokoi; Atsushi Yonezawa; Daiki Hira; Tomohiro Handa; Kiminobu Tanizawa; Shunsaku Nakagawa; Masahiro Tsuda; Yasuaki Ikemi; Ryo Itotani; Hironori Yoshida; Motoo Nomura; Junichi Matsubara; Kosaku Murakami; Hiroaki Ozasa; Manabu Muto; Tomohiro Terada

  Journal of pharmaceutical health care and sciences, 27 Aug. 2024, Peer-reviewed

  Access this paper :

  
• MET遺伝子増幅を有する胆嚢原発神経内分泌がんに対しCapmatinibが奏効した一例

  山村 彰吾; 金井 雅史; 竹内 康英; 近藤 知大; 吉岡 正博; 松原 淳一; 松本 繁巳; 武藤 学

  日本癌治療学会学術集会抄録集, Oct. 2023

  
• Response to capmatinib in a patient with neuroendocrine carcinoma of the gallbladder origin harboring MET amplification.

  Shogo Yamamura; Masashi Kanai; Yasuhide Takeuchi; Natsuko Okita; Tomohiro Kondo; Masahiro Yoshioka; Junichi Matsubara; Shigemi Matsumoto; Manabu Muto

  International cancer conference journal, Apr. 2024

  
• Combination therapy with WEE1 inhibition and trifluridine/tipiracil against esophageal squamous cell carcinoma

  Trang H. Nguyen Vu; Osamu Kikuchi; Shinya Ohashi; Tomoki Saito; Tomomi Ida; Yukie Nakai; Yang Cao; Yoshihiro Yamamoto; Yuki Kondo; Yosuke Mitani; Shigeki Kataoka; Tomohiro Kondo; Chikatoshi Katada; Atsushi Yamada; Junichi Matsubara; Manabu Muto

  Cancer Science, 19 Sep. 2023, Peer-reviewed

  
• A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial

  Yohei Chiba; Kazuki Sudo; Yuki Kojima; Hitomi Okuma; Shinji Kohsaka; Ryunosuke Machida; Masahiko Ichimura; Kenta Anjo; Kazumi Kurishita; Natsuko Okita; Kenichi Nakamura; Ichiro Kinoshita; Masanobu Takahashi; Junichi Matsubara; Hitoshi Kusaba; Kan Yonemori; Masamichi Takahashi

  BMC Cancer, 09 Aug. 2022, Peer-reviewed

  
• First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities

  Junichi Matsubara; Kumi Mukai; Tomohiro Kondo; Masahiro Yoshioka; Hidenori Kage; Katsutoshi Oda; Ryo Kudo; Sadakatsu Ikeda; Hiromichi Ebi; Kei Muro; Ryuji Hayashi; Nahomi Tokudome; Nobuyuki Yamamoto; Manabu Muto

  JAMA Network Open, 17 Jul. 2023, Peer-reviewed, Lead author

  
• Clinical analysis of outcomes and prognosis related to percutaneous endoscopic gastrostomy among the elderly

  MATSUBARA JUN'ICHI; FUJITA YOSHIYUKI; HASHIMOTO AKEMI; NIINAMI CHIKAKO; ITO TOSHIYUKI; MARUYAMA MASATAKA

  日本消化器病学会雑誌, 05 Mar. 2005

  
• Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer: prospective multicenter observational study.

  Tomohiro Kondo; Masashi Kanai; Junichi Matsubara; Daisuke Yamaguchi; Takashi Ura; Tadayuki Kou; Toshinao Itani; Motoo Nomura; Taro Funakoshi; Akira Yokoyama; Keitaro Doi; Masashi Tamaoki; Michio Yoshimura; Norimitsu Uza; Takahiro Yamada; Toshihiko Masui; Sachiko Minamiguchi; Shigemi Matsumoto; Hideki Ishikawa; Manabu Muto

  Medical oncology (Northwood, London, England), 11 Apr. 2023

  
• Association between preanalytical factors and tumor mutational burden estimated by NGS-based multiplex gene panel assay

  Quy Pham Nguyen; Kanai Masashi; Kou Takayuki; Kondo Tomohiro; Yamamoto Yoshihiro; Matsubara Junichi; Hiroshima Akinori; Mochizuki Hiroaki; Sakuma Tomohiro; Fukuyama Keita; Matsumoto Shigemi; Muto Manabu

  ANNALS OF ONCOLOGY, Oct. 2019, Peer-reviewed

  
• Association between sample characteristics and tumor mutational burden estimated by next-generation sequencing-based multiplex gene panel assay.

  Quy Pham Nguyen; Kanai Masashi; Kou Tadayuki; Kondo Tomohiro; Yamamoto Yoshihiro; Matsubara Junichi; Hiroshima Akinori; Mochizuki Hiroaki; Sakuma Tomohiro; Fukuyama Keita; Matsumoto Shigemi; Muto Manabu

  JOURNAL OF CLINICAL ONCOLOGY, 10 Mar. 2019, Peer-reviewed

  
• MULTICENTER PHASE II STUDY OF BOLUS 5-FU/LV + WEEKLY PACLITAXEL (FLTAX) AS 1ST-LINE THERAPY FOR ADVANCED GASTRIC CANCER

  Akihito Tsuji; Junichi Matsubara; Ken Kato; Norisuke Nakayama; Akira Yoshioka; Yasuhiro Shimada

  ANNALS OF ONCOLOGY, Nov. 2010, Peer-reviewed

  
• 抗がん薬未投与進行がん症例におけるがんゲノム医療の可能性

  近藤 知大; ファムグェン・クィー; 松原 淳一; 船越 太郎; 土井 恵太郎; 廣橋 研志郎; 吉岡 正博; 金井 雅史; 松本 繁己; 武藤 学

  日本内科学会雑誌, Feb. 2020

  
• がん遺伝子パネル検査における二次的所見疑い症例に対する生殖細胞系列確認検査の適応

  近藤 知大; 金井 雅史; 山本 佳宏; 福山 啓太; 松原 淳一; ファムグェン・クィー; 吉岡 正博; 山田 崇弘; 小杉 眞司; 武藤 学

  日本癌治療学会学術集会抄録集, Oct. 2021

  
• Experimental model for the irradiation-mediated abscopal effect and factors influencing this effect

  Baba K; Nomura M; Ohashi S; Hiratsuka T; Nakai Y; Saito T; Kondo Y; Fukuyama K; Kikuchi O; Yamada A; Matsubara J; Hirohashi K; Mitani Y; Mizumoto A; Muto M

  Am J Cancer Res, 2020, Peer-reviewed

  Access this paper :

  
• エタノール投与後マウスにおける食道組織内DNAアダクト(N2 ethylidene2' dG)の動態

  馬場 希一郎; 大橋 真也; 天沼 裕介; 廣橋 研志郎; 松原 淳一; 松田 知成; 武藤 学

  日本食道学会学術集会プログラム・抄録集, Jun. 2017

  
• Biomarker Discovery of Pancreatic and Gastrointestinal Cancer by 2DICAL: 2-Dimensional Image-Converted Analysis of Liquid Chromatography and Mass Spectrometry.

  Ono M; Kamita M; Murakoshi Y; Matsubara J; Honda K; Miho B; Sakuma T; Yamada T

  International journal of proteomics, 2012, Peer-reviewed

  
• 新しい血中低分子タンパク分離濃縮技術を用いた血液前処理法と 2DICAL による膵がん診断マーカーの開発

  松原 淳一; 尾野 雅哉; 本田 一文; 田中 祥徳; 小林 道元; 鄭 基晩; 柳沢 宏次; 佐久間 朋寛; 桑原 秀也; 千葉 勉; 広橋 説雄; 山田 哲司

  日本プロテオーム学会大会要旨集, 2010

  
• Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay.

  Pham Nguyen Quy; Masashi Kanai; Keita Fukuyama; Tadayuki Kou; Tomohiro Kondo; Yoshihiro Yamamoto; Junichi Matsubara; Akinori Hiroshima; Hiroaki Mochizuki; Tomohiro Sakuma; Mayumi Kamada; Masahiko Nakatsui; Yuji Eso; Hiroshi Seno; Toshihiko Masui; Kyoichi Takaori; Sachiko Minamiguchi; Shigemi Matsumoto; Manabu Muto

  The oncologist, Dec. 2019, Peer-reviewed

  
• HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function.

  Yosuke Mitani; Shinya Ohashi; Osamu Kikuchi; Yukie Nakai; Tomomi Ida; Ayaka Mizumoto; Yoshihiro Yamamoto; Tomoki Saito; Shigeki Kataoka; Junichi Matsubara; Atsushi Yamada; Masashi Kanai; Shigemi Matsumoto; Hiroaki Sakai; Kiyotsugu Yoshikawa; Eijiro Nakamura; Manabu Muto

  Scientific reports, 02 Jun. 2022

  Access this paper :

  
• Germline sequencing for presumed germline pathogenic variants via tumor-only comprehensive genomic profiling.

  Tomohiro Kondo; Yoshihiro Yamamoto; Keita Fukuyama; Masashi Kanai; Atsushi Yamada; Junichi Matsubara; Pham Nguyen Quy; Masahiro Yoshioka; Takahiro Yamada; Sachiko Minamiguchi; Shigemi Matsumoto; Shinji Kosugi; Manabu Muto

  International journal of clinical oncology, 14 May 2022

  
• Inter-assay variability of next-generation sequencing-based gene panels.

  Pham Nguyen Quy; Keita Fukuyama; Masashi Kanai; Tadayuki Kou; Tomohiro Kondo; Masahiro Yoshioka; Junichi Matsubara; Tomohiro Sakuma; Sachiko Minamiguchi; Shigemi Matsumoto; Manabu Muto

  BMC medical genomics, 15 Apr. 2022

  Access this paper :

  
• [Precision Medicine Provided by National Health Insurance].

  Manabu Muto; Tomohiro Kondo; Junichi Matsubara; Masashi Kanai; Shigemi Matsumoto; Kanami Ashida; Junko Suga; Kumi Mukai

  Gan to kagaku ryoho. Cancer & chemotherapy, Aug. 2020

  
• Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.

  Tomohiro Kondo; Junichi Matsubara; Pham Nguyen Quy; Keita Fukuyama; Motoo Nomura; Taro Funakoshi; Keitaro Doi; Yuichi Sakamori; Masahiro Yoshioka; Akira Yokoyama; Masashi Tamaoki; Tadayuki Kou; Kenshiro Hirohashi; Atsushi Yamada; Yoshihiro Yamamoto; Sachiko Minamiguchi; Masakazu Nishigaki; Takahiro Yamada; Masashi Kanai; Shigemi Matsumoto; Manabu Muto

  Cancer science, Jan. 2021

  Access this paper :

  
• Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report

  Yosuke Mitani; Masashi Kanai; Tadayuki Kou; Shigeki Kataoka; Keitaro Doi; Junichi Matsubara; Shinya Ohashi; Shigemi Matsumoto; Manabu Muto

  BMC Cancer, Dec. 2020

  
• BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer.

  Tomohiro Kondo; Masashi Kanai; Junichi Matsubara; Pham Nguyen Quy; Keita Fukuyama; Yoshihiro Yamamoto; Takahiro Yamada; Masakazu Nishigaki; Sachiko Minamiguchi; Masayuki Takeda; Kazuto Nishio; Shigemi Matsumoto; Manabu Muto

  Pancreas, 02 Oct. 2020

  
• Protective effects of Alda-1, an ALDH2 activator, on alcohol-derived DNA damage in the esophagus of human ALDH2*2 (Glu504Lys) knock-in mice.

  Kenshiro Hirohashi; Shinya Ohashi; Yusuke Amanuma; Yukie Nakai; Tomomi Ida; Kiichiro Baba; Yosuke Mitani; Ayaka Mizumoto; Yoshihiro Yamamoto; Osamu Kikuchi; Junichi Matsubara; Atsushi Yamada; Shin'ichi Miyamoto; Hiroshi Seno; Tomonari Matsuda; Manabu Muto

  Carcinogenesis, 22 Apr. 2020

  Access this paper :

  
• Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma.

  Ayaka Mizumoto; Shinya Ohashi; Mayumi Kamada; Tomoki Saito; Yukie Nakai; Kiichiro Baba; Kenshiro Hirohashi; Yosuke Mitani; Osamu Kikuchi; Junichi Matsubara; Atsushi Yamada; Tsukasa Takahashi; Hyunjin Lee; Yasushi Okuno; Masashi Kanai; Manabu Muto

  Journal of gastroenterology, Aug. 2019

  Access this paper :

  
• Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.

  Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M

  Journal of experimental & clinical cancer research : CR, Aug. 2017, Peer-reviewed

  
• Identification of Adipophilin as a Potential Plasma Biomarker for Colorectal Cancer Using Label-Free Quantitative Mass Spectrometry and Protein Microarray

  Junichi Matsubara; Kazufumi Honda; Masaya Ono; Shigeki Sekine; Yoshinori Tanaka; Michimoto Kobayashi; Giman Jung; Tomohiro Sakuma; Shoji Nakamori; Naohiro Sata; Hideo Nagai; Tatsuya Ioka; Takuji Okusaka; Tomoo Kosuge; Akihiko Tsuchida; Masashi Shimahara; Yohichi Yasunami; Tsutomu Chiba; Tesshi Yamada

  CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, Oct. 2011, Peer-reviewed

  Access this paper :

  
• Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma

  Natsuko Tsuda Okita; Ken Kato; Daisuke Takahari; Yoshinori Hirashima; Takako E. Nakajima; Junichi Matsubara; Tetsuya Hamaguchi; Yasuhide Yamada; Yasuhiro Shimada; Hirokazu Taniguchi; Kuniaki Shirao

  GASTRIC CANCER, Jun. 2011, Peer-reviewed

  
• Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray

  Yusuke Murakoshi; Kazufumi Honda; Shizuka Sasazuki; Masaya Ono; Ayako Negishi; Junichi Matsubara; Tomohiro Sakuma; Hideya Kuwabara; Shoji Nakamori; Naohiro Sata; Hideo Nagai; Tatsuya Ioka; Takuji Okusaka; Tomoo Kosuge; Masashi Shimahara; Yohichi Yasunami; Yoshinori Ino; Akihiko Tsuchida; Tatsuya Aoki; Shoichiro Tsugane; Tesshi Yamada

  CANCER SCIENCE, Mar. 2011, Peer-reviewed

  
• Phase II Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel as First-Line Therapy for Advanced Gastric Cancer

  Junichi Matsubara; Yasuhiro Shimada; Ken Kato; Yushi Nagai; Satoru Iwasa; Takako E. Nakajima; Tetsuya Hamaguchi; Yasuhide Yamada; Seiichi Takagi; Kazuma Kobayashi; Akira Yoshioka; Norisuke Nakayama; Akihito Tsuji

  ONCOLOGY, 2011, Peer-reviewed

  
• Use of quantitative shotgun proteomics to identify fibronectin 1 as a potential plasma biomarker for clear cell carcinoma of the kidney

  Akira Yokomizo; Michiko Takakura; Yae Kanai; Tomohiro Sakuma; Junichi Matsubara; Kazufumi Honda; Seiji Naito; Tesshi Yamada; Masaya Ono

  CANCER BIOMARKERS, 2011, Peer-reviewed

  
• Reduced Plasma Level of CXC Chemokine Ligand 7 in Patients with Pancreatic Cancer

  Junichi Matsubara; Kazufumi Honda; Masaya Ono; Yoshinori Tanaka; Michimoto Kobayashi; Giman Jung; Koji Yanagisawa; Tomohiro Sakuma; Shoji Nakamori; Naohiro Sata; Hideo Nagai; Tatsuya Ioka; Takuji Okusaka; Tomoo Kosuge; Akihiko Tsuchida; Masashi Shimahara; Yohichi Yasunami; Tsutomu Chiba; Setsuo Hirohashi; Tesshi Yamada

  CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, Jan. 2011, Peer-reviewed

  
• 膵癌の診断バイオマーカーとしての血中CXCL7濃度(Reduced plasma level of CXC chemokine ligand 7 as a biomarker for pancreatic cancer)

  松原 淳一; 本田 一文; 尾野 雅哉; 中森 正二; 永井 秀雄; 井岡 達也; 奥坂 拓志; 小菅 智男; 土田 明彦; 千葉 勉; 広橋 説雄; 山田 哲司

  日本癌学会総会記事, Aug. 2010

  
• 胃がんにおけるHER2、EGFR、IGF-1R、VEGFRの発現と化学療法の治療成績

  松原 淳一; 平島 詳典; 山田 康秀

  癌と化学療法, Aug. 2010, Peer-reviewed

  
• [Impact of HER2, EGFR, IGF-1R, and VEGFR expressions on the outcome of chemotherapy for advanced gastric cancer].

  Junichi Matsubara; Yoshinori Hirashima; Yasuhide Yamada

  Gan to kagaku ryoho. Cancer & chemotherapy, Aug. 2010, Peer-reviewed

  
• Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment

  Junichi Matsubara; Masaya Ono; Kazufumi Honda; Ayako Negishi; Hideki Ueno; Takuji Okusaka; Junji Furuse; Koh Furuta; Emiko Sugiyama; Yoshiro Saito; Nahoko Kaniwa; Junichi Sawada; Ayako Shoji; Tomohiro Sakuma; Tsutomu Chiba; Nagahiro Saijo; Setsuo Hirohashi; Tesshi Yamada

  MOLECULAR & CELLULAR PROTEOMICS, Apr. 2010, Peer-reviewed

  
• Prolyl 4-hydroxylation of α-fibrinogen. A novel protein modification revealed by plasma proteomics

  Masaya Ono; Junichi Matsubara; Kazufumi Honda; Tomohiro Sakuma; Tomoyo Hashiguchi; Hiroshi Nose; Shoji Nakamori; Takuji Okusaka; Tomoo Kosuge; Naohiro Sata; Hideo Nagai; Tatsuya Ioka; Sachiko Tanaka; Akihiko Tsuchida; Tatsuya Aoki; Masashi Shimahara; Yohichi Yasunami; Takao Itoi; Fuminori Moriyasu; Ayako Negishi; Hideya Kuwabara; Ayako Shoji; Setsuo Hirohashi; Tesshi Yamada

  Journal of Biological Chemistry, 16 Oct. 2009, Peer-reviewed

  
• Vascular Endothelial Growth Factor Receptor Expression as a Prognostic Marker for Survival in Colorectal Cancer

  Natsuko Tsuda Okita; Yasuhide Yamada; Daisuke Takahari; Yosinori Hirashima; Junichi Matsubara; Ken Kato; Tetsuya Hamaguchi; Kuniaki Shirao; Yasuhiro Shimada; Hirokazu Taniguchi; Tadakazu Shimoda

  JAPANESE JOURNAL OF CLINICAL ONCOLOGY, Sep. 2009, Peer-reviewed

  
• Identification of a Predictive Biomarker for Hematologic Toxicities of Gemcitabine

  Junichi Matsubara; Masaya Ono; Ayako Negishi; Hideki Ueno; Takuji Okusaka; Junji Furuse; Koh Furuta; Emiko Sugiyama; Yoshiro Saito; Nahoko Kaniwa; Junichi Sawada; Kazufumi Honda; Tomohiro Sakuma; Tsutomu Chiba; Nagahiro Saijo; Setsuo Hirohashi; Tesshi Yamada

  JOURNAL OF CLINICAL ONCOLOGY, May 2009, Peer-reviewed

  
• Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer

  Yoshinori Hirashima; Yasuhide Yamada; Junichi Matsubara; Daisuke Takahari; Natsuko Okita; Atsuo Takashima; Ken Kato; Tetsuya Hamaguchi; Kuniaki Shirao; Yasuhiro Shimada; Hirokazu Taniguchi; Tadakazu Shimoda

  CANCER SCIENCE, Feb. 2009, Peer-reviewed

  
• Relationships of Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor Expression to Clinical Outcomes in Patients with Colorectal Cancer

  Daisuke Takahari; Yasuhide Yamada; Natuko T. Okita; Takuya Honda; Yoshinori Hirashima; Junichi Matsubara; Atsuo Takashima; Ken Kato; Tetsuya Hamaguchi; Kuniaki Shirao; Yasuhiro Shimada; Tadakazu Shimoda

  ONCOLOGY, 2009, Peer-reviewed

  
• A phase I study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer

  Junichi Matsubara; Yasuhiro Shimada; Atsuo Takashima; Daisuke Takahari; Yoshinori Hirashima; Natsuko T. Okita; Takako E. Nakajima; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Kuniaki Shirao

  JAPANESE JOURNAL OF CLINICAL ONCOLOGY, Aug. 2008, Peer-reviewed

  
• Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer

  Junichi Matsubara; Yasuhide Yamada; Yoshinori Hirashima; Daisuke Takahari; Natsuko T. Okita; Ken Kato; Tetsuya Hamaguchi; Kuniaki Shirao; Yasuhiro Shimada; Tadakazu Shimoda

  CLINICAL CANCER RESEARCH, May 2008, Peer-reviewed

  
• Ultrasound-guided percutaneous pancreatic tumor biopsy in pancreatic cancer: a comparison with metastatic liver tumor biopsy, including sensitivity, specificity, and complications

  Junichi Matsubara; Takuji Okusaka; Chigusa Morizane; Masafumi Ikeda; Hideki Ueno

  JOURNAL OF GASTROENTEROLOGY, Mar. 2008, Peer-reviewed

  
• Combination of O-6-methylguanine-DNA methyltransferase and thymidylate synthase for the prediction of fluoropyrimidine efficacy

  Takako Eguchi Nakajima; Yasuhide Yamada; Tadakazu Shimoda; Junichi Matsubara; Ken Kato; Tetsuya Hamaguchi; Yasuhiro Shimada; Yoshihiro Okayama; Toshinori Oka; Kuniaki Shirao

  EUROPEAN JOURNAL OF CANCER, Feb. 2008, Peer-reviewed

  
• Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer

  J. Matsubara; T. Nishina; Y. Yamada; T. Moriwaki; T. Shimoda; T. Kajiwara; T. E. Nakajima; K. Kato; T. Hamaguchi; Y. Shimada; Y. Okayama; T. Oka; K. Shirao

  BRITISH JOURNAL OF CANCER, Feb. 2008, Peer-reviewed

  
• Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer

  Junichi Matsubara; Yasuhide Yamada; Takako E. Nakajima; Ken Kato; Tetsuya Hamaguchi; Kuniaki Shirao; Yasuhiro Shimada; Tadakazu Shimoda

  ONCOLOGY, 2008, Peer-reviewed

  
• Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy

  A. Takashima; K. Shirao; Y. Hirashima; D. Takahari; N. Okita; S. Akatsuka; T. Eguchi Nakajima; J. Matsubara; H. Yasui; T. Asakawa; K. Kato; T. Hamguchi; K. Muro; Y. Yamada; Y. Shimada

  DISEASES OF THE ESOPHAGUS, 2008, Peer-reviewed

  
• 切除不能・再発胃癌に対する5-FU+/-LV+Paclitaxel併用療法(FLTAX)の第I相試験

  松原 淳一; 島田 安博; 高島 淳生; 高張 大亮; 平島 詳典; 沖田 南都子; 中島 貴子; 加藤 健; 濱口 哲弥; 山田 康秀; 白尾 国昭

  日本癌治療学会誌, Sep. 2007, Peer-reviewed

  
• A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.

  Hideki Ueno; Takuji Okusaka; Masafumi Ikeda; Yoriko Ishiguro; Chigusa Morizane; Junichi Matsubara; Junji Furuse; Hiroshi Ishii; Michitaka Nagase; Kohei Nakachi

  Oncology, 2005, Peer-reviewed

  

Misc.

• CGP test before the 1st-line chemotherapy for patients with advanced solid tumors

  Junichi Matsubara

  Pharma Medica, May 2024, Invited, Lead author, Last author, Corresponding author

  
• Predictive markers for chemotherapy toxicity: An important factor in personalized therapy

  Junichi Matsubara; Masaya Ono; Tesshi Yamada

  European journal of Clinical and Medical Oncology, 2010

  
• A new blood biomarker discovered by 2DICAL-2-Dimensional Image Converted Analysis of Liquid chromatography and mass spectrometry

  尾野雅哉; 松原淳一; 本田一文; 佐久間朋寛; 橋口朋代; 能勢博; 増田万里; 高倉美智子; 下重美紀; 桑原秀也; 正路章子; 廣橋説雄; 山田哲司

  日本プロテオーム学会大会プログラム・抄録集, 2009

  
• 癌治療の進歩(肝・胆・膵) 膵癌の非手術療法例の遠隔成績 当院における10年間648例の検討

  池田 公史; 奥坂 拓志; 上野 秀樹; 竹迫 賀子; 森実 千種; 松原 淳一; 名嶋 弥菜

  日本癌治療学会誌, Sep. 2004

  
• 進行胆道癌および肝内胆管癌に対するUFTの第二相試験

  池田 公史; 奥坂 拓志; 上野 秀樹; 古瀬 純司; 石井 浩; 森実 千種; 松原 淳一; 名嶋 弥菜

  胆道, Aug. 2004

  
• 食道癌術後妊娠中に発生した吻合部再発に対し化学放射線療法を施行し生児を得た1例

  野村 基雄; 佐藤 千尋; 玉置 将司; 松原 淳一; 藤井 康太; 坂中 克行; 角田 茂; 山田 香; 千草 義継; 武藤 学

  日本食道学会学術集会プログラム・抄録集, Jun. 2018

  
• 進行膵癌に対するgemcitablineとS-1の併用療法の臨床第1相試験

  上野 秀樹; 奥坂 拓志; 池田 公史; 竹迫 賀子; 森実 千種; 松原 淳一; 名嶋 弥菜; 古瀬 純司; 石井 浩

  日本癌治療学会誌, Sep. 2004

  
• 遠隔転移を有する膵癌に対するgemcitabineとcisplatinの併用療法 臨床第2相試験

  松原 淳一; 上野 秀樹; 奥坂 拓志; 池田 公史; 竹迫 賀子; 森実 千種; 名嶋 弥菜

  日本癌治療学会誌, Sep. 2004

  
• 局所進行膵癌に対する5FU併用放射線療法後の維持化学療法 Gemcitabineと5FUの比較検討

  池田 公史; 奥坂 拓志; 伊藤 芳紀; 加賀美 芳和; 上野 秀樹; 竹迫 賀子; 森実 千種; 松原 淳一; 名嶋 弥菜; 池田 恢

  日本癌治療学会誌, Sep. 2004

  
• 包括的がんゲノムプロファイリングにおける二次的所見疑いバリアントの絞り込み基準

  近藤 知大; 金井 雅史; 山本 佳宏; 福山 啓太; 山田 敦; 吉岡 正博; 松原 淳一; 松本 繁己; 小杉 眞司; 武藤 学

  日本内科学会雑誌, Feb. 2022

  
• Biomarker discovery via proteomics analyzing system of 2DICAL

  尾野 雅哉; 紙田 正博; 松原 淳一

  細胞, Oct. 2012

  
• 大腿部皮下埋め込み型中心静脈ポートのカテーテル断裂を認めた1例

  近藤 知大; 土井 恵太郎; 佐藤 千尋; 片岡 滋貴; 玉置 将司; 吉岡 正博; 野村 基雄; 天沼 裕介; 松原 淳一; 高 忠之; 金井 雅史; 松本 繁巳; 武藤 学

  日本癌治療学会学術集会抄録集, Oct. 2017

  
• 再発・非治癒例の内科治療 (特集 胃がん--最新の治療と看護(2))

  松原 淳一; 島田 安博

  がん看護, Nov. 2006

  
• 大腸がん化学療法--あらたな標準治療体系 (第5土曜特集 がんの化学療法--最新治療コンセンサス) -- (進歩する標準治療)

  松原 淳一; 島田 安博

  医学のあゆみ, 29 Oct. 2005

  
• 質量分析の消化器疾患の診療・研究への応用(第4回) プロテオーム解析によるがん診断と治療への道

  尾野 雅哉; 紙田 正博; 松原 淳一; 山田 哲司

  分子消化器病, Dec. 2012

  
• 2DICALプロテオーム解析手法を用いた癌診断治療標的分子の開発(The discovery of molecular targets for cancer diagnosis and therapy by a proteome platform: 2DICAL)

  尾野 雅哉; 紙田 正博; 五十嵐 文子; 松原 淳一; 根岸 綾子; 山田 哲司

  日本癌学会総会記事, Sep. 2011

  
• ゲムシタビン単剤療法における血液毒性予測マーカーの開発

  松原 淳一; 尾野 雅哉; 上野 秀樹; 奥坂 拓志; 古瀬 純司; 古田 耕; 鹿庭 なほ子; 澤田 純一; 西條 長宏; 広橋 説雄; 山田 哲司

  日本分子腫瘍マーカー研究会誌, Feb. 2010

  
• ゲムシタビン単剤療法における血液毒性予測マーカーの開発

  松原 淳一; 尾野 雅哉; 上野 秀樹; 奥坂 拓志; 古瀬 純司; 古田 耕; 鹿庭 なほ子; 澤田 純一; 西條 長宏; 広橋 説雄; 山田 哲司

  日本分子腫瘍マーカー研究会プログラム・講演抄録, Sep. 2009

  
• 切除不能膵がんに対するゲムシタビン単剤療法の血液毒性予測マーカーの開発(Identification of a biomarker that predicts hematological adverse events associated with gemcitabine treatment)

  松原 淳一; 尾野 雅哉; 古瀬 純司; 上野 秀樹; 奥坂 拓志; 鹿庭 なほ子; 澤田 純一; 千葉 勉; 西條 長宏; 広橋 説雄; 山田 哲司

  日本癌学会総会記事, Sep. 2008

  
• 2DICAL法によるバイオマーカー探索(Biomarker Discovery by 2-Dimensional Image Converted Analysis of Liquid Chromatography and Mass Spectromery (2DICAL))

  根岸 綾子; 尾野 雅哉; 松原 淳一; 筑井 恵美子; 小村 健; 廣橋 説雄; 山田 哲司

  日本癌学会総会記事, Aug. 2007

  
• ショットガンプロテオミクス法により同定された腎がんの新規腫瘍マーカー、fibronectin 1

  横溝 晃; 高倉 美智子; 金井 弥栄; 佐久間 朋寛; 松原 淳一; 本田 一文; 内藤 誠二; 山田 哲司; 尾野 雅哉

  日本泌尿器科学会雑誌, Mar. 2012

  
• 切除不能膵がんにおけるゲムシタビン単剤療法の新規予後因子および予後予測モデルの開発(Survival prediction for pancreatic cancer patients receiving gemcitabine treatment)

  松原 淳一; 尾野 雅哉; 本田 一文; 古瀬 純司; 上野 秀樹; 奥坂 拓志; 鹿庭 なほ子; 澤田 純一; 千葉 勉; 西條 長宏; 広橋 説雄; 山田 哲司

  日本癌学会総会記事, Aug. 2009

  
• ホルマリン固定パラフィン包埋組織を用いた舌扁平上皮癌のバイオマーカーの探索(Quantitative proteomics using formalin-fixed paraffin-embedded (FFPE) tissue of squamous cell carcinoma of the tongue)

  根岸 綾子; 尾野 雅哉; 本田 一文; 松原 淳一; 村越 雄介; 廣橋 説雄; 小村 健; 山田 哲司

  日本癌学会総会記事, Sep. 2008

  
• ANTI-TUMOR EFFECT OF THERACURMIN (R), HIGHLY BIOAVAILABLE CURCUMIN, FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA

  Ayaka Mizumoto; Shinya Ohashi; Kenshiro Hirohashi; Yukie Nakai; Junichi Matsubara; Masashi Kanai; Manabu Muto

  GASTROENTEROLOGY, Apr. 2017

  
• EGFR inhibitors exert different effects on epithelial-like and mesenchymal-like esophageal squamous carcinoma cells

  Masahiro Yoshioka; Shinya Ohashi; Tomomi Ida; Yukie Nakai; Osamu Kikuchi; Yusuke Amanuma; Jun'ichi Matsubara; Atsushi Yamada; Shin'ichi Miyamoto; Manabu Muto

  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Nov. 2016

  
• 上皮様、間葉様の食道扁平上皮がんに対するEGFR阻害剤による分化誘導効果

  吉岡 正博; 大橋 真也; 菊池 理; 玉置 将司; 松原 淳一; 森 由希子; 宮本 心一; 武藤 学

  日本癌学会総会記事, Oct. 2016

  
• Comprehensive genomic profiling for chemotherapy-naive advanced gastrointestinal malignancies

  Tomohiro Kondo; Quy Pham Nguyen; Junichi Matsubara; Keita Fukuyama; Motoo Nomura; Taro Funakoshi; Mari Funakoshi; Hitomi Sakamoto; Kanami Ashida; Kumi Mukai; Shinji Uemoto; Yoshiharu Sakai; Hiroshi Seno; Sachiko Minamiguchi; Hironori Haga; Shinji Kosugi; Masashi Kanai; Shigemi Matsumoto; Manabu Muto

  JOURNAL OF CLINICAL ONCOLOGY, Feb. 2020

  
• 大腸癌におけるIGF-1R、EGFR、VEGFRの発現と予後予測

  津田 南都子; 山田 康秀; 高張 大亮; 平島 詳典; 松原 淳一; 加藤 健; 濱口 哲弥; 島田 安博; 白尾 国昭; 下田 忠和

  日本癌治療学会誌, Sep. 2007

  
• 胃癌患者におけるVEGF-R1、2、3、IGF-1R、EGFR、HER-2の発現と予後への影響

  平島 詳典; 山田 康秀; 松原 淳一; 高張 大亮; 津田 南都子; 高島 淳生; 加藤 健; 濱口 哲弥; 白尾 国昭; 島田 安博; 下田 忠和

  日本癌治療学会誌, Sep. 2007

  
• 本邦における大腸癌化学療法の成績 切除不能進行・再発大腸癌患者の初回化学療法例を対象としたmodified FOLFOX6療法の有効性および安全性の検討

  平島 詳典; 加藤 健; 高島 淳生; 赤塚 壮太郎; 高張 大亮; 津田 南都子; 江口 貴子; 松原 淳一; 安井 久晃; 濱口 哲弥; 室 圭; 山田 康秀; 白尾 国昭; 島田 安博

  日本癌治療学会誌, Sep. 2006

  
• DICを合併した進行胃癌に対する化学療法の治療成績 前化学療法の有無による治療成績の比較

  高島 淳生; 白尾 国昭; 赤塚 壮太郎; 高張 大亮; 津田 南津子; 平島 詳典; 江口 貴子; 松原 淳一; 加藤 健; 濱口 哲弥; 室 圭; 山田 康秀; 島田 安博

  日本癌治療学会誌, Sep. 2006

  
• 当院における切除不能大腸癌に対するFOLFOX療法failure後の2nd line化学療法の現状

  高張 大亮; 加藤 健; 平島 詳典; 赤塚 壮太郎; 津田 南都子; 高島 淳生; 江口 貴子; 松原 淳一; 安井 久晃; 濱口 哲弥; 室 圭; 山田 康秀; 白尾 國昭; 島田 安博

  日本癌治療学会誌, Sep. 2006

  
• modified FOLFOX6療法における末梢神経障害の検討

  堀田 洋介; 加藤 健; 高張 大亮; 平島 詳典; 津田 南都子; 高島 淳生; 松原 淳一; 濱口 哲弥; 山田 康秀; 白尾 国昭; 島田 安博

  日本癌治療学会誌, Sep. 2006

  
• 消化管間質腫瘍(GIST)に対するイマチニブの治療成績

  赤塚 壮太郎; 白尾 国昭; 高島 淳生; 高張 大亮; 平島 詳典; 津田 南都子; 江口 貴子; 松原 淳一; 加藤 健; 濱口 哲弥; 山田 康秀; 島田 安博

  日本癌治療学会誌, Sep. 2006

  
• 胃癌化学療法の効果予測因子としての核酸代謝酵素mRNA発現に関する探索的研究

  松原 淳一; 山田 康秀; 江口 貴子; 安井 久晃; 加藤 健; 後藤 歩; 濱口 哲弥; 室 圭; 島田 安博; 白尾 国昭; 下田 忠和; 岡山 佳弘; 杉本 芳一; 岡 俊範

  日本癌治療学会誌, Sep. 2005

  
• 大腸癌化学療法における効果予測因子としての核酸代謝酵素mRNA発現に関する探索的研究

  江口 貴子; 山田 康秀; 松原 淳一; 安井 久晃; 加藤 健; 後藤 歩; 濱口 哲弥; 室 圭; 島田 安博; 白尾 国昭; 岡山 佳弘; 杉本 芳一; 岡 俊範; 下田 忠和

  日本癌治療学会誌, Sep. 2005

  
• Clinical Stage I食道癌に対する化学放射線療法における照射方法の臨床的検討

  赤塚 壮太郎; 室 圭; 江口 貴子; 松原 淳一; 加藤 健; 安井 久晃; 後藤 歩; 濱口 哲弥; 山田 康秀; 島田 安博; 白尾 国昭; 伊藤 芳紀; 今井 敦; 加賀美 芳和

  日本癌治療学会誌, Sep. 2005

  
• Confirmatory germline testing for presumed germline pathogenic variants using tumor-only testing.

  Tomohiro Kondo; Takahiro Yamada; Masahiro Yoshioka; Masakazu Nishigaki; Yoshihiro Yamamoto; Tadayuki Kou; Junichi Matsubara; Masashi Kanai; Shigemi Matsumoto; Manabu Muto; Shinji Kosugi

  JOURNAL OF CLINICAL ONCOLOGY, May 2021

  
• A predictive model for hematologic toxicities of gemcitabine

  松原 淳一; 尾野 雅哉; 山田 哲司

  血液・腫瘍科, Jan. 2010

  
• Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells

  Masahiro Yoshioka; Shinya Ohashi; Tomomi Ida; Yukie Nakai; Osamu Kikuchi; Yusuke Amanuma; Junichi Matsubara; Atsushi Yamada; Shin'ichi Miyamoto; Mitsuteru Natsuizaka; Hiroshi Nakagawa; Tsutomu Chiba; Hiroshi Seno; Manabu Muto

  JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, Aug. 2017

  
• Predictive biomarker for hematological toxicities of gemcitabine identified by proteomics

  Junichi Matsubara; Masaya Ono; Hideki Ueno; Takuji Okusaka; Junji Furuse; Koh Furuta; Emiko Sugiyama; Yoshiro Saito; Nahoko Kaniwa; Junichi Sawada; Tomohiro Sakuma; Tsutomu Chiba; Nagahiro Saijo; Tesshi Yamada

  CANCER RESEARCH, May 2009

  
• Retrospective study of the correlation between creatinine clearance and oxaliplatin-related cumulative neurotoxicity

  H. Kawakami; Y. Yamada; Y. Hirashima; D. Takahari; N. Tsuda; J. Matsubara; K. Kato; T. Hamaguchi; Y. Shimada; K. Shirao

  ANNALS OF ONCOLOGY, 2007

  
• Impact of dihydrofolate reductase (DHFR) and thymidylate synthase (TS) on outcomes of postoperative patients with gastric cancer.

  J. Matsubara; Y. Yamada; T. Shimoda; T. Eguchi; T. Hamaguchi; Y. Shimada; Y. Okayama; Y. Sugimoto; T. Oka; K. Shirao

  JOURNAL OF CLINICAL ONCOLOGY, Jun. 2006

  

Awards

• 01 Apr. 2009

  American Association for Cancer Research, AACR-ITO EN, Ltd. Scholar-in-Training Award
• 01 Sep. 2010

  日本プロテオーム学会, The Incitement Award of the Japanese Proteomics Society

External funds: Kakenhi

• CDKN3 as a new target of anti-cancer treatment overcoming the resistance to cytotoxic chemotherapy

  Grant-in-Aid for Scientific Research (C)

  Basic Section 53010:Gastroenterology-related

  Kyoto University

  JUNICHI MATSUBARA

  From 01 Apr. 2019, To 31 Mar. 2022, Project Closed

  食道癌;大腸癌;CDKN3;抗がん薬;抗癌剤;薬剤耐性;細胞周期;分子シミュレーション

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19K08393/
• The mechanism of chemotherapy resistance in colon cancer stem cells and epithelial mesenchymal transition colon cancer cells

  Grant-in-Aid for Research Activity Start-up

  Kyoto University

  Junichi Matsubara

  From 26 Aug. 2016, To 31 Mar. 2018, Project Closed

  がん幹細胞;大腸癌;上皮間葉形質転換;抗癌剤;治療抵抗性;化学療法;CDKN3;癌;上皮間葉転換;癌幹細胞

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-16H06899/
• CDKN3 inhibitor as a new compound to overcome the resistance to cytotoxic chemotherapy

  Grant-in-Aid for Scientific Research (C)

  Basic Section 53010:Gastroenterology-related

  Kyoto University

  松原 淳一

  From 01 Apr. 2022, To 31 Mar. 2025, Granted

  CDKN3;食道癌;抗がん薬;大腸癌;抗癌剤

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22K08012/
• Elucidation of the mechanism of CDKN3 involved in cell cycle regulation of cancer stem-like cells of esophageal squamous cell carcinoma

  Grant-in-Aid for Scientific Research (C)

  Basic Section 53010:Gastroenterology-related

  Kyoto University

  松原 淳一

  From 01 Apr. 2025, To 31 Mar. 2028, Granted

  癌幹細胞;食道癌;CDKN3;細胞周期

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-25K11273/

External funds: others

• 血液プロテオミクス解析を用いた大腸癌分子標的治療の個別化に関する新しい血中ペプチドマーカーの開発と臨床応用

  平成２２年度安田記念医学財団　若手癌研究助成

  From 01 Dec. 2010, To 30 Nov. 2011

  松原　淳一
• 膵癌転移機序に関わる癌幹細胞由来タンパクの新規同定とその制御による新しい膵癌治療法の開発

  公益財団法人　武田科学振興財団　2011年度医学系研究奨励

  From 01 Nov. 2011

  松原　淳一
• 癌幹細胞の薬物耐性機序解明と治療標的開発

  平成２４年度上原記念生命科学財団　海外留学助成金リサーチフェローシップ

  From 01 May 2013, To 30 Apr. 2014

  松原　淳一

Education

Teaching subject(s)

• From 01 Apr. 2025, To 31 Mar. 2026

  Clinical Overview of Medicine B

  C319, Fall, Faculty of Pharmaceutical Sciences, 1
• From 01 Apr. 2025, To 31 Mar. 2026

  Clinical Overview of Medicine G

  3229, Spring, Faculty of Medicine, 1
• From 01 Apr. 2024, To 31 Mar. 2025

  Clinical Overview of Medicine B

  C319, Fall, Faculty of Pharmaceutical Sciences, 1
• From 01 Apr. 2024, To 31 Mar. 2025

  Clinical Overview of Medicine B

  3224, Fall, Faculty of Medicine, 1
• From 01 Apr. 2024, To 31 Mar. 2025

  Advanced Cancer Nursing Lecture I

  M298, Spring, Graduate School of Medicine, 2
• From 01 Apr. 2023, To 31 Mar. 2024

  Advanced Cancer Nursing Lecture I

  M298, Spring, Graduate School of Medicine, 2

Academic, Social Contribution

Committee Memberships

• From Apr. 2022, To Present

  Committee of Public Relations, Japanese Society of Medical Oncology
• From Apr. 2020, To Present

  Committee of Cancer Genome Medical Coordinater, Japanese Society of Medical Oncology